Overview
Considering our upcoming press conference, it is important to remember that we all represent Mylan and coordinate the message we want to project out in public. Bearing in mind the recent distractions, we need to reaffirm who we are and what we stand for. It is imperative to reiterate that Mylan is a cutting edge, innovative company that delivers high-quality, lifesaving products. Situation
A recent price adjustment of our EpiPen Auto-Injector product has triggered a media firestorm. Suddenly, our organization is under a microscope and we are facing pressure from the public and government entities alike. Outraged parents many government officials are calling for investigation into our company and our practices. All this negative
…show more content…
The EpiPen Auto-Injector’s contribution to our company’s financial performance currently represents about 10 %. Additionally, Mylan’s sales revenue from two pack EpiPen is approximately 45%, which covers manufacturing, distributing, enhancing, and investing in future development of high-quality products.
We need to reaffirm our position as a company delivering high-quality products. One of our competitors suffered from product recall due to possibility of delivering incorrect dosage. The rest our competing products captured only about 7% of market share due to reluctance of customer switching products. Therefore, this is an evidence of our customer trusting and preferring our EpiPen over competing products.
Doing our art in saving lives, we have increased an access to EpiPen by issuing a saving card to users that will effectively cut the cost of two pack EpiPen by $300. In addition, we have doubled the eligibility for patient assistance program, which practically eliminates out of pocket cost for uninsured or underinsured families and
The current debate over the Mylan Company’s near monopoly of the epinephrine market through its EpiPen shows what can happen without monopoly regulation. While the cost to produce an Epipen is around $30, the price to the consumer is around $300 each. The economic implications for a family that needs to keep the device on hand to save a life can be excessively high, the emotional results of not having one when you need one are debilitating. This monopoly is further enhanced by state-enforced regulations requiring that schools keep EpiPens in stock and the, so-called, EpiPen law enacted in 2013, which leave little incentive for other pharmaceutical companies to develop their own technology for fast-acting emergency devices. (Bartolone, 2016) Breaking Mylan’s monopoly will not only lead to new product development but lower prices for consumers for a life-saving delivery
The EpiPen device automatically injects a drug called epinephrine, which reverses potentially deadly allergic reactions. It is the only device of its kind available in the United States. Millions depend on carrying the device at all times. For decades the EpiPen was available at a low cost until the Mylan Company purchased it in 2007. Since then, the price has risen over 400% creating a public backlash of media reports, social media petitions, and politician’s calling out Mylan executives to explain the reason for the price raise. Lack of compassion and appearance of greed has tarnished the public image of the company. Mylan has begun looking for ways of rebuilding their image by releasing compensation to the public in the form of generic cheaper EpiPens and payment assistance to eligible patients, but it might be too little too late in this current ongoing communication crisis event.
Allstar Brands’ brand management team will make decisions based on the assumptions gained from corporate standings and market research. Allround cold medication will capitalize on its high brand awareness and solid market share to increase revenue through promotional allowances, product diversification and bigger direct to consumer promotions. Our primary focus is direct channel distribution to mass merchandisers, large grocery stores and chain drugstores. New product reformulation for children’s medicine and adult capsule are expected to increase market share and long-term profitability. We predict a reduction in advertising costs due to strong brand awareness.
As the Communications Coordinator for the Cobbs National Drug Manufacturer (CNDM) there is rising concern around recent events from the media exposure on the adverse effects one of our nationally advertised medications has had on the Chief-of-Police. According to Athena du Pre, PhD, “Lack of communication can lead to duplicated efforts, costly (and sometimes life-threatening) delays, frustration, and wasted time” (Du Pre, 2005, p. 289) and our goal is to maintain open communication. Today’s meeting will help identify several ways to deliver our message. Today’s meeting will help to brainstorm
Serial Killers have been studied by psychologists, anthropologist and sociologists for years. In the following case study I will be talking about Robert Pickton. Robert Pickton is Canada’s most notorious serial killer, he was charged with 26 murder cases in 2006. I will analyze Roberts’s case with theories from psychology, sociology and anthropology. Psychology can tell us about Robert’s individual behaviour. Sociology can tell us about how the people and society around Robert affected him and Anthropology can tell us how his culture affected him.
The Story of the Three Bears is a classic tale that has been around since 1837. The tale is known to have many different authors dated back from the 1800’s. Authors such as Eleanor Mure and Robert Southey are the most known authors for their different publications of this tale. The authors included different villains in each edition. The history of Goldilocks and the Three Bears, became important because the many historical differences led to the conclusion that Robert Southey was the original author. In “The Story of the Three Bears,” the historical context featured exemplify the differences between the authors and their personal editions.
Pharmed First Inc. is a widely successful chain pharmaceutical company with 85 drugstores located in Canada’s Atlantic provinces. George Brenner is one of the 6 regional managers and Angela MacFee is a store manager in a mall located in Dartmouth. One of MacFee’s loyal customers have purchased 9 packages of Diet Magic on September 2011 however wanted to return them on May 2012. Subsequently, MacFee reacted hastily and defensively, arguing with Johnston in spite of Pharmed First Inc. return policy (Figure 1). As a result, Johnston wrote a letter to Frank Chen, the president of Pharmed First Inc. and told Brenner to deal with it. He proposed that the company gives Johnston a $500 voucher and that MacFee apologizes. However, MacFee remained inflexible as she also challenged Brenner’s authority.
This happened on two occasions, the first in 1982 and the second in 1986. These episodes could have been devastating to the McNeil company by drastic decrease in consumption of the Tylenol products. The McNeil company rallied to the situation to counter this possible decrease in consumption. According to "Laurels: The National Business Hall of Fame", Tylenol's share in the one billion dollar analgesic market commanded thirty-five percent of the market before the 1982 incident. At the time of these episodes, consumer trust was damaged and market share decreased to seven percent. By February 1983, Tylenol had regained a twenty-four percent share of the market(Diary of an Amazing Comeback). In the 1990's, Tylenol again reached its thirty-five percent of the market which at this time accounted for a two billion dollar market(Laurels: The National Business Hall of Fame, Fortune). By regaining their share of the market, this demonstrated that the consumers had faith in the McNeil company's ability to produce safe and trustworthy products, i.e. Tylenol, for their comfort and happiness.
Recently, there had been a controversy over the rise in pharmaceutical costs involving the EpiPen in the United States. The EpiPen, also known as adrenaline/epinephrine, is a widely used injection that is used to treat allergic reactions. This generic drug has been available for many years. The EpiPen controversy is a prime example of how monopoly
This case study focuses Burroughs Wellcome and their drug Retrovir. Retrovir is a drug that treats AIDS and AID-related complications. In 1987, Burroughs Wellcome obtained approval from the FDA to market azidothymidine (AZT), also known as Retrovir, as a treatment for AIDS. Retrovir was the only kind of drug on the market. Because of this, many critics accused Burroughs Wellcome of price-gouging, as the price of Retrovir was $188 for a hundred 100mg capsules sold to wholesalers. The president of Burroughs Wellcome, T.E Haigler, defended the high price, stating it was due to uncertainty in the market, the possibility of new drug therapies, and profit margins created by new drugs. Even though Retrovir’s price was dropped 20 percent in December 1987, and 20 percent more in September 1989, due to the House of Representatives launching an investigation, there was still pressure to lower the price. The big question faced in this case is what is Burroughs Wellcome’s next move regarding pricing?
During this time the first DTC print advertisement for Merck an “antipneumococcal vaccine, Pneumovax(pneumococcal vaccine polyvalent) was printed in Reader’s Digest (Ventola).” That created a chain effect and shortly later “Boots Pharmaceuticals ran the first DTC broadcast advertisement, which promoted the lower price of its prescription brand of ibuprofen (Rufen), compared with Motrin (Ventola).” Today, the US pharmaceutical industry spends $3.1 billion on advertising prescription drugs directly to consumers.
In a competitive market to which Johnson and Johnson operates, the smallest of errors can lead to consequences which can cut revenue. When large mistakes occur, millions of dollars are lost, and even worse, there is a loss of customer confidence. Johnson and Johnson has had numerous recalls in their consumer healthcare division recently, which rocked the organization’s once sound image, and diminished its profits. These recalls have hurt Johnson and Johnson’s stocks and cost the company about $900 million in sales last year (Rockoff, 2011).
The Idea of “freedom from fear” has changed since the time of the famous “The four freedoms” speech by the late Franklin Roosevelt in 1941 but only on what the fear is. At the time the speech was given, America had isolationist policies that emerged at the end of World War I. Fears were deeply rooted in another economic decline as the nation had just experienced but also in a new threat. World War II was well under way and Roosevelt felt America should intervene to protect freedom and democracy. Now in 2017, almost 76 years later, the fear is focused on advancement in technologies and liberating people from under oppressive regimes and governments as said in a welcoming speech by President Barack Obama in 2012 .
In period five, we introduced the line extension Allright; a 12-Hr muli-symptom relief capsule. We decided this extension would be successful, as the allergy market is very small and had an entrenched competitor. Therefore, while we were aware of potential cannibalization, we believed that the targeted market (retirees, empty nesters, and young singles) would have sufficient demand for our product. We also reasoned that this target was far enough removed from Allround’s to gain additional market share without taking any from Allround. However, this was not the case, as cannibalization was a pressing issue. Market share was gained at the expense of Allround.
The problematic issue for Bristol-Myers was to position its new aspirin drug to the potential customers and decide a good price which can not only make it acceptable by the customers, but also give a fair profit to the company. In other words, the company had to formulate an effective marketing and promotional strategy for its new drug, Datril. The company was not merely willing to establish its new brand in the analgesic market; the main issue was to establish this new brand in the presence of a strong competitor, Tylenol.